Abstract:, anidulafungin ( AFG ,and combinationsof FLC + AFG,AFG + AMB,andFLC + AMBagainst 17 C.albicans isolates obtained from the oral cavity of cancer patients. Isolates that had not been exposed to antifungals, served as a control group. Colony counts were performed at 0, 2, 4, 6, and 24 h after a brief ( 1 h ) antifungal exposure. Results: The FLC had no detectable post-antifungal effect independent of antifungal concentration and resembled drug-free FLC ( control ) . When all AMB and AFG were compared with FLC, significant variations in the post-antifungal effect were observed. Combining AFG and AMB with FLC resulted in effective activity compared to FLC alone. Combination regimens were rated as indifferent in general. Interestingly, low dosages of the AFG displayed increasing fungistatic action as it neared a fungistatic endpoint against C. albicans isolates ( n = 17 ) . Conclusion: Our findings suggest that brief exposure to AFG, in combination with FLC and AMB, at low concentrations of the medicines utilized, could be effective in the evaluation and optimization of new dosage regimens to manage candidiasis. However, future research will look at the clinical utility of our findings. albicans is the most common cause of nosocomial and are with morbidity and in However, limited therapeutic approaches against invasive candidiasis are available. The rise in antifungal resistance highlights the urgent need to develop new therapeutic options and novel this was an in regard of the showed a significant decrease in the number of loads,similar to the group with ATTAF-1 and ATTAF-2. Nevertheless, the results this study that the use of and ATTAF-2 as a therapeutic agent can exert significant in and in vivo antifungal effects C.albicans ,increasing animal and significantly decreasing loads. Conclusion: Although we have identified two new compounds, ATTAF-1 and ATTAF-2, as novel promising Candidates for the of studies of ATTAF-1 and ATTAF-2 activity and their action mechanisms in animal models are warranted to enhance our understanding and establish their efficacy. Antifungal-resistant dermatophytosis is an emerging threat with cases of chronic,recurrent infection reported from several countriesincluding India. Additionally, the rapidspread of infections involves person-to-personspread.Our results suggest that a clonal outbreak of a T. indotineae strain is circulating in multiple states in India. Current plans are to expand the geographic scope of the study by including over 10 countries from Europe, Middle East, and the Americas. This work will allow the publichealth community to better understandthe emergence and transmissionof antifungal-resistant dermatophytosis worldwide.

Antifungal activity of the repurposed drug disulfiram against Cryptococcus neoformans

Use of Haploid Model of Candida Albicans to Uncover Mechanism of Action of a Novel Antifungal Agent.

Synergistic Effect of the Combination of Deferoxamine and Fluconazole in Vitro and in Vivo Against Fluconazole-Resistant Candida Spp.

Antifungal Effect of Vitamin D3 against Cryptococcus neoformans Coincides with Reduced Biofilm Formation, Compromised Cell Wall Integrity, and Increased Generation of Reactive Oxygen Species

Synergic effect of deferoxamine combined with fluconazole against fluconazole-resistant <i>Candida</i> Spp. through inhibited Cek1 MAPK signaling pathway

ASLdC3: A Derivative of Acidic Sophorolipid Disrupts Mitochondrial Function, Induces ROS Generation, and Inhibits Biofilm Formation in Candida albicans

Antifungal and antibiofilm effect of duloxetine hydrochloride against Cryptococcus neoformans and Cryptococcus gattii

Discovery of Novel 7-Hydroxy-5-oxo-4,5-dihydrothieno[3,2-b]pyridine-6-carboxamide Derivatives with Potent and Selective Antifungal Activity against Cryptococcus Species

Synthesis and antifungal evaluation of novel triazole derivatives bearing a pyrazole-methoxyl moiety

Synergistic Antifungal Effects of Curcumin Derivatives As Fungal Biofilm Inhibitors with Fluconazole.

Synergistic and drug-resistant reversing effects of diorcinol D combined with fluconazole against Candida albicans.

Antifungal Activity, Synergism with Fluconazole or Amphotericin B and Potential Mechanism of Direct Current against Candida albicans Biofilms and Persisters

Design, synthesis and evaluation of novel deferasirox derivatives with high antifungal potency in vitro and in vivo

Synergic Effect of Deferoxamine Combined with Fluconazole Against Fluconazole-Resistant Candida Spp. Through Inhibited Cek1 MAPK Signaling Pathway

Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents

Discovery of Novel Sertraline Derivatives as Potent Anti- Cryptococcus Agents

Discovery and Repurposing of Pharmaceutical Agents as Antifungals: activity against

Combination of fluconazole with natural compounds: A promising strategy to manage resistant Candida albicans infections

Repurposing an Inhibitor of Ribosomal Biogenesis with Broad Anti-Fungal Activity

Deep-learning based repurposing of FDA-approved drugs against Candida albicans dihydrofolate reductase and molecular dynamics study

Synthetic Naphthofuranquinone Derivatives Are Effective in Eliminating Drug-Resistant Candida albicans in Hyphal, Biofilm, and Intracellular Forms: An Application for Skin-Infection Treatment